“A new era in Menkes disease management: the disease-modifying impact of Zycubo (copper histidinate)”
Open Access
- 14 May 2026
- journal article
- Published by Wolters Kluwer Health in Annals of Medicine & Surgery
- Vol. 88 (6) , 3048-3050
Abstract
No abstract availableThis publication has 11 references indexed in Scilit:
- ZYCUBO (copper histidinate)Clinical Therapeutics, 2026
- Zycubo (copper histidinate), the first treatment for pediatric Menkes diseaseTrends in Pharmacological Sciences, 2026
- Single-arm clinical trials: design, ethics, principlesBMJ Supportive & Palliative Care, 2024
- Health-Related Quality of Life and Family Functioning of Primary Caregivers of Children with Menkes DiseaseJournal of Clinical Medicine, 2023
- Copper Toxicity Associated With an ATP7A-Related Complex PhenotypePediatric Neurology, 2021
- Menkes disease: what a multidisciplinary approach can doJournal of Multidisciplinary Healthcare, 2016
- Novel mutations and clinical outcomes of copper-histidine therapy in Menkes disease patientsMetabolic Brain Disease, 2014
- Menkes diseaseEuropean Journal of Human Genetics, 2009
- Solution Structure of Physiological Cu(His)2: Novel Considerations into Imidazole CoordinationInorganic Chemistry, 2009
- Neonatal Diagnosis and Treatment of Menkes DiseaseNew England Journal of Medicine, 2008